Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - AVEO PHARMACEUTICALS, INC. | aveo-ex322_10.htm |
| EX-32.1 - EX-32.1 - AVEO PHARMACEUTICALS, INC. | aveo-ex321_6.htm |
| EX-31.2 - EX-31.2 - AVEO PHARMACEUTICALS, INC. | aveo-ex312_9.htm |
| EX-31.1 - EX-31.1 - AVEO PHARMACEUTICALS, INC. | aveo-ex311_7.htm |
| EX-21.1 - EX-21.1 - AVEO PHARMACEUTICALS, INC. | aveo-ex211_8.htm |
| EX-10.22 - EX-10.22 - AVEO PHARMACEUTICALS, INC. | aveo-ex1022_295.htm |
| EX-10.21 - EX-10.21 - AVEO PHARMACEUTICALS, INC. | aveo-ex1021_510.htm |
| 10-K - 10-K - AVEO PHARMACEUTICALS, INC. | aveo-10k_20171231.htm |
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-165530, 333-175390, 333-189565 and 333-221838 and Form S-3 No. 333-221837) of AVEO Pharmaceuticals, Inc. of our reports dated March 13, 2018, with respect to the consolidated financial statements of AVEO Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of AVEO Pharmaceuticals, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2017.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 13, 2018